NASDAQ:ENOB

Enochian Biosciences (ENOB) Stock Forecast, Price & News

$0.78

-0.04 (-4.89%)

(As of 01:45 PM ET)

Compare

Today's Range: $0.78
▼
$0.88
50-Day Range: $0.82
▼
$1.30
52-Week Range: $0.72
▼
$4.20

Volume: 31,577 shs
Average Volume: 51,989 shs
Market Capitalization: $45.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Enochian Biosciences (NASDAQ:ENOB) Stock

Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Receive ENOB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enochian Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENOB Stock News Headlines

May 31, 2023 | americanbankingnews.com

Enochian Biosciences Inc. (NASDAQ:ENOB) Short Interest Update

May 18, 2023 | americanbankingnews.com

Enochian Biosciences Inc. (NASDAQ:ENOB) Sees Large Decrease in Short Interest

June 2, 2023 | Edge On The Street (Ad)

Is Graphite the New Lithium?

Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.

April 15, 2023 | markets.businessinsider.com

Grabar Law Office Investigates Claims on Behalf of Shareholders of Enochian Biosciences Inc. (ENOB)

April 3, 2023 | finance.yahoo.com

Enochian BioSciences’ CEO Letter to Shareholders

March 29, 2023 | finance.yahoo.com

Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher

March 13, 2023 | finanznachrichten.de

Enochian BioSciences, Inc.: Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements

March 13, 2023 | msn.com

Enochian BioSciences regains Nasdaq compliance by filing pending reports

June 2, 2023 | Edge On The Street (Ad)

The Graphite Shortage Story You're Not Being Told

Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.

March 13, 2023 | finance.yahoo.com

Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements

February 23, 2023 | msn.com

Enochian gets Nasdaq listing deficiency notice for not filing 10-Q

February 23, 2023 | finance.yahoo.com

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022

January 19, 2023 | reuters.com

ENOB.O - | Stock Price & Latest News | Reuters

November 30, 2022 | seekingalpha.com

Enochian gets Nasdaq notice for delaying crucial filings

November 30, 2022 | finance.yahoo.com

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022

October 24, 2022 | finance.yahoo.com

Biotech Co-Founder, Facing Murder-for-Hire Charges, Accused of Fabricating Data

October 24, 2022 | finance.yahoo.com

Enochian BioSciences Forges Ahead With Focused Approach, Promising Future

October 21, 2022 | finance.yahoo.com

Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Annual Report on Form 10-K

October 19, 2022 | finanznachrichten.de

Enochian BioSciences, Inc.: Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology Platform

October 17, 2022 | finance.yahoo.com

Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology Platform

October 13, 2022 | finance.yahoo.com

Enochian Biosciences, Inc. (ENOB)

September 26, 2022 | benzinga.com

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Enochian Biosciences, Inc. with Losses of $100,000 to Contact the Firm

September 24, 2022 | tmcnet.com

ENOCHIAN DEADLINE ALERT: Bragar Eagel & Squire, P.C.

September 23, 2022 | benzinga.com

Edelson Lechtzin LLP Reminds Enochian Biosciences, Inc. Investors of the Impending Lead Plaintiff Deadline

September 20, 2022 | benzinga.com

CLASS ACTION UPDATE for ENOB, MNSO and PLTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

September 19, 2022 | benzinga.com

SHAREHOLDER DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Enochian Biosciences, Inc. with Losses of $100,000 to Contact the Firm

September 16, 2022 | markets.businessinsider.com

Pre-market Movers: ATXG, FWBI, IDYA, ENOB, LUCY…

See More Headlines

ENOB Price History

30 days | 90 days | 365 days | Advanced Chart

ENOB Company Calendar

Today: 6/02/2023
Next Earnings (Estimated): 6/02/2023
Fiscal Year End: 6/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ENOB
CUSIP: N/A
CIK: 1527728
Web: www.enochianbio.com
Phone: (305) 918-1980
Fax: N/A
Employees: 11
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.82)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-113,430,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -154.69%
Return on Assets: -130.66%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.33
Quick Ratio: 0.33

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.13 per share
Price / Book: 0.69

Miscellaneous

Outstanding Shares: 58,280,000
Free Float: 45,625,000
Market Cap: $45.46 million
Optionable: Not Optionable
Beta: 1.22

Key Executives

Mark Richard Dybul
Executive Vice Chairman & Chief Executive Officer

François Binette
Chief Operating Officer

Luisa Puche
Chief Financial Officer & Secretary

Greg Duczynski
Senior Vice President-Clinical Operations

Joseph R. Cohen
Director-Research & Discovery

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ENOB Stock - Frequently Asked Questions

How have ENOB shares performed in 2023?: Enochian Biosciences' stock was trading at $1.03 at the beginning of 2023. Since then, ENOB stock has decreased by 24.3% and is now trading at $0.78.
View the best growth stocks for 2023 here.
Are investors shorting Enochian Biosciences?: Enochian Biosciences saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 1,430,000 shares, a decrease of 6.5% from the April 30th total of 1,530,000 shares. Based on an average daily volume of 58,400 shares, the days-to-cover ratio is presently 24.5 days. Currently, 5.3% of the company's stock are short sold.
View Enochian Biosciences' Short Interest.
When is Enochian Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, June 2nd 2023.
View our ENOB earnings forecast.
What other stocks do shareholders of Enochian Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Enochian Biosciences investors own include AcelRx Pharmaceuticals (ACRX), Aptinyx (APTX), Axcella Health (AXLA), Aytu BioPharma (AYTU), Calithera Biosciences (CALA), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), DURECT (DRRX), Geron (GERN) and

What is Enochian Biosciences' stock symbol?: Enochian Biosciences trades on the NASDAQ under the ticker symbol "ENOB."
Who are Enochian Biosciences' major shareholders?: Enochian Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.21%), Two Sigma Advisers LP (0.10%), Two Sigma Investments LP (0.10%), HRT Financial LP (0.07%) and Belvedere Trading LLC (0.00%). Insiders that own company stock include Carl Forest Sandler and Serhat Gumrukcu.
View institutional ownership trends.
How do I buy shares of Enochian Biosciences?: Shares of ENOB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Enochian Biosciences' stock price today?: One share of ENOB stock can currently be purchased for approximately $0.78.
How much money does Enochian Biosciences make?: Enochian Biosciences (NASDAQ:ENOB) has a market capitalization of $45.46 million. The company earns $-113,430,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.
How can I contact Enochian Biosciences?: Enochian Biosciences' mailing address is 2080 Century Park EastSuite 906, Los Angeles CA, 90067. The official website for the company is www.enochianbio.com. The company can be reached via phone at (305) 918-1980 or via email at ir@enochianbio.com.

This page (NASDAQ:ENOB) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial